Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study
Author(s) -
Sebastiano Bruno Solerte,
Francesca D’Addio,
Roberto Trevisan,
Elisabetta Lovati,
Antonio Rossi,
Ida Pastore,
Marco Dell’Acqua,
Elio Ippolito,
Cristiana Scaranna,
Rosalia Bellante,
Silvia Galliani,
Alessandro Roberto Dodesini,
Giuseppe Lepore,
Francesca Geni,
Roberta Maria Fiorina,
E Catena,
Angelo Guido Corsico,
Riccardo Colombo,
Marco Mirani,
Carlo De Riva,
S. E. Oleandri,
Reza Abdi,
Joseph V. Bonventre,
Stefano Rusconi,
Franco Folli,
Antonio Di Sabatino,
Gian Vincenzo Zuccotti,
Massimo Galli,
Paolo Fiorina
Publication year - 2020
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc20-1521
Subject(s) - medicine , sitagliptin , type 2 diabetes , retrospective cohort study , diabetes mellitus , hazard ratio , pneumonia , population , observational study , endocrinology , confidence interval , environmental health
Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom